Colorectal Cancer
Colorectal cancer (CRC) is the second most common cause of cancer-related death in the United States and is the leading cause of death in men aged <50 years. Read More ›
By William King
Updates to the screening guidelines for colorectal cancer (CRC) from the National Comprehensive Cancer Network (NCCN) include lowering the initial screening age for average-risk individuals and second- and third-degree family members with CRC, as well as an extension in the interval for surveillance colonoscopy for low-risk individuals. Read More ›
Adagrasib (MRTX849), an inhibitor of the KRASG12C mutation, showed promising activity as monotherapy and in combination with cetuximab (Erbitux) in patients with metastatic colorectal cancer (CRC) in the phase 1/2 KRYSTAL-1 trial. Read More ›
By William King
The first-line immunotherapy combination of nivolumab (Opdivo) and low-dose ipilimumab (Yervoy) continues to show robust, durable clinical benefit, with a deepening of response, in patients with microsatellite instability high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colorectal cancer (CRC), according to results presented at the ASCO 2020 virtual annual meeting. Read More ›
There is a new standard of care in the first-line treatment setting for the subset of patients with advanced colorectal cancer (CRC) that is associated with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR), according to data presented at the ASCO 2020 virtual annual meeting. Read More ›
By Wayne Kuznar
San Francisco, CA—The combination of encorafenib (Braftovi) plus cetuximab (Erbitux), with or without binimetinib (Mektovi), improved the quality of life based on patient-reported assessments better than current standard of care in the treatment of patients with metastatic colorectal cancer (CRC) and BRAF V600E mutation, according to the BEACON CRC study, which was presented at the 2020 Gastrointestinal Cancers Symposium. Read More ›
By Wayne Kuznar
The addition of the PD-1 inhibitor durvalumab (Imfinzi) and the CTLA-4 inhibitor tremelimumab to best supportive care improved overall survival (OS) by >2 months compared with best supportive care alone in patients with advanced refractory colorectal cancer (CRC), according to results of the phase 2 Canadian Cancer Trials Group (CCTG) CO.26 clinical trial. Read More ›
The FDA granted accelerated approval to nivolumab based on a notable clinical benefit in a subset of patients who progressed after receiving the standard first-line chemotherapy with fluoropyrimidine, oxaliplatin, and irinotecan.
Read More ›
By Wayne Kuznar
A starting dose of regorafenib (Stivarga) 80 mg daily with dose escalation to 160 mg daily was better tolerated than starting at 160 mg daily, with a trend toward improved survival in the management of patients with metastatic colorectal cancer.
Read More ›Overwhelming evidence supports a chemopreventive benefit of aspirin on colorectal cancer (CRC), and a potential effect on other cancers and cardiovascular risk. Read More ›